A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer

Objective To evaluate the correlation of clinical effects and reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer. Methods We reviewed retrospectively the clinical records of patients with metastatic breast cancer treated with docetaxel and statistically analyzed the correlation between clinical effects and reasonable doses of docetaxel. Results The objective response rate and clinical benefit rate of docetaxol in patients with metastatic breast cancer were 27.0% and 35.0%, respectively, and the median progression free survival （ PFS ） was 5.0 （3.8-6.3） months. In the analysis at a single dose level, the clinical benefit rate and PFS of the ≥90.0 mg/㎡ docetaxel group were superior to that of the 〈 90.0 mg/㎡ group （P = 0.008, P = O. 045 ）. Multi-dose level group stratified analysis showed that the docetaxel 〈75.0 mg/㎡ group was better than the 75.0-84.9 mg/㎡ PFS group （P =0.018）, and the ≥95.0 mg/㎡ group was better than the 75.0-84.9 mg/㎡ group （ P = 0. 048 ）. In patients who received 〉 third line treatment or previously received paelitaxel adjuvant therapy, the PFS of the ≥ 94.9 mg/㎡ docetaxel group was 6.0 months, better than the 3.0 months of the 75.0 - 84.9 mg/㎡ group （ P = 0. 031 ; P = 0.021 ）. Condusiola There is a clear correlation between clinical effects and reasonable doses of docetaxel salvage therapy in patients with metastatic breast cancer. Key words: Breast neoplasms;  Neoplasm metastasis;  Dose-response relationship, drug; Treatment outcome